Chengnuo Regenerative Medicine Technology

Chengnuo Regenerative Medicine is a clinical-stage biotechnology company based in Chengdu, China, focused on the development of induced pluripotent stem cell (iPSC) derived therapies. The company leverages its proprietary iPSC technology platform to produce standardized, off-the-shelf cell products designed to treat a variety of degenerative and inflammatory conditions. Its lead program, an iPSC-derived mesenchymal stem cell (iMSC) therapy, has received IND clearance for the treatment of knee osteoarthritis. Chengnuo's research and development efforts are closely integrated with clinical insights from the West China Hospital of Sichuan University. The company aims to revolutionize regenerative medicine by providing scalable and high-quality cell-based treatments for global markets.